PHARMACY

Everett Labs acquires Quinnova Pharmaceuticals from Amneal Enterprises

BY Alaric DeArment

CHATHAM, N.J. — Everett Labs has acquired Quinnova Pharmaceuticals from Amneal Enterprises, Everett said Monday.

Everett Labs, a subsidiary of Spain-based Exeltis, said the purchase would help it expand into the U.S. dermatology and women’s health markets. Financial terms of the deal were not disclosed.

"We believe dermatology is a very attractive opportunity for Everett in the U.S. market, and after an extensive search, we found Quinnova to be a great organization to help us grow this business," Everett Labs CEO Lucas Sigman said. "Quinnova offers important synergies for Everett with its innovative and entrepreneurial culture, as well as its dedicated and focused sales team, which is similar to Everett."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Valeant buys Solta Medical

BY Alaric DeArment

LAVAL, Quebec — Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.

The Canadian drug maker said the $2.92-per-share acquisition represented a 40% premium over Solta’s closing share price on Friday. Solta develops, manufactures and markets energy-based medical device systems for such cosmetic medical procedures as skin tightening, improving skin texture and others.

"The acquisition of Solta will bring tremendous value to Valeant’s current aesthetic and, together with our previous acquisitions, will create the broadest aesthetic portfolio in the industry," Valeant chairman and CEO J. Michael Pearson said. "Solta’s leading aesthetic devices are a natural fit with Valeant’s facial injectables, professional skin care products and physician-dispensed products, and will establish Valeant in a strong leadership position as we continue to build our presence in the aesthetic market."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

EMD Serono releases redesigned injector pen for infertility

BY Alaric DeArment

ROCKLAND, Mass. — A redesigned version of an injector pen used to treat infertility is available for distribution in the United States, the manufacturer said Monday.

EMD Serono, a subsidiary of German drug maker Merck KGaA, said that Gonal-f RFF Redi-ject, a disposable, pre-filled pen used for the drug Gonal-f RFF (follitropin alfa), had become available. The Food and Drug Administration approved the redesigned pen in October. Merck KGaA operates in the United States under the name EMD in order to avoid confusion with U.S.-based Merck & Co.

"This device was designed with feedback from healthcare professionals, patients and significant others," EMD Serono SVP and head of U.S. fertility and endocrinology Craig Millian said. "EMD Serono has a long heritage of fertility expertise and is committed to strengthening that legacy. Adding this device to our product portfolio helps to further our mission, which is to create, innovate and advocate for people who want to have a child, with the goal of reducing barriers to treatment."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES